Effect of long-term therapy on the pharmacodynamics of levodopa: Relation to on-off phenomenon

John Nutt, William Woodward, Julie Carter, Stephen T. Gancher

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

To determine how the response to levodopa is altered by long-term therapy, we examined the dose response to 2-hour infusions of levodopa in three groups of parkinsonian patients: those who were previously untreated, those who exhibited stable responses, and those who exhibited fluctuating responses to levodopa therapy, using tapping speed as an index of bradykinesia. The baseline tapping speed was greater in the patients with stable responses than in the untreated patients, probably representing a “long-duration response” to levodopa therapy. A “short-duration response”, indicated by an increase in tapping speed lasting hours, was observed in most patients in all groups. The onset of the short-duration effect was more rapid and the incremental increase in tapping speed was twice as large in the patients with fluctuating responses compared with the untreated patients and patients with stable responses. The duration of the short-duration effect was greatest in the untreated group but did not differ between the groups with stable and fluctuating responses. Dyskinesia was not observed in any of the de novo patients but was observed in three of 12 patients with stable responses and eight of nine patients with fluctuating responses to levodopa therapy. Dyskinesia appeared before or with the antiparkinsonian effects in patients with stable responses, giving no indication of a higher threshold for dyskinesia in these patients compared with those with fluctuating responses. The plasma half-life clearance, volume of distribution, and maximum plasma concentrations of levodopa did not differ among groups. We conclude that (1) part of what has been considered an extended short-duration response to levodopa therapy in patients with stable responses represents instead the long-duration response; (2) a short-duration response, albeit subtle, is present in most patients from the initiation of levodopa therapy; and (3) an increase in the magnitude of the short-duration response and the appearance of dyskinesia cause the fluctuations to become clinically important, whereas a shortening of the duration of the response is not critical.

Original languageEnglish (US)
Pages (from-to)1123-1130
Number of pages8
JournalArchives of Neurology
Volume49
Issue number11
DOIs
StatePublished - 1992

Fingerprint

Levodopa
Dyskinesias
Therapeutics
Therapy
Antiparkinson Agents
Hypokinesia
Half-Life

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Effect of long-term therapy on the pharmacodynamics of levodopa : Relation to on-off phenomenon. / Nutt, John; Woodward, William; Carter, Julie; Gancher, Stephen T.

In: Archives of Neurology, Vol. 49, No. 11, 1992, p. 1123-1130.

Research output: Contribution to journalArticle

@article{2c83d3d37b674f40a6769016bdcf188b,
title = "Effect of long-term therapy on the pharmacodynamics of levodopa: Relation to on-off phenomenon",
abstract = "To determine how the response to levodopa is altered by long-term therapy, we examined the dose response to 2-hour infusions of levodopa in three groups of parkinsonian patients: those who were previously untreated, those who exhibited stable responses, and those who exhibited fluctuating responses to levodopa therapy, using tapping speed as an index of bradykinesia. The baseline tapping speed was greater in the patients with stable responses than in the untreated patients, probably representing a “long-duration response” to levodopa therapy. A “short-duration response”, indicated by an increase in tapping speed lasting hours, was observed in most patients in all groups. The onset of the short-duration effect was more rapid and the incremental increase in tapping speed was twice as large in the patients with fluctuating responses compared with the untreated patients and patients with stable responses. The duration of the short-duration effect was greatest in the untreated group but did not differ between the groups with stable and fluctuating responses. Dyskinesia was not observed in any of the de novo patients but was observed in three of 12 patients with stable responses and eight of nine patients with fluctuating responses to levodopa therapy. Dyskinesia appeared before or with the antiparkinsonian effects in patients with stable responses, giving no indication of a higher threshold for dyskinesia in these patients compared with those with fluctuating responses. The plasma half-life clearance, volume of distribution, and maximum plasma concentrations of levodopa did not differ among groups. We conclude that (1) part of what has been considered an extended short-duration response to levodopa therapy in patients with stable responses represents instead the long-duration response; (2) a short-duration response, albeit subtle, is present in most patients from the initiation of levodopa therapy; and (3) an increase in the magnitude of the short-duration response and the appearance of dyskinesia cause the fluctuations to become clinically important, whereas a shortening of the duration of the response is not critical.",
author = "John Nutt and William Woodward and Julie Carter and Gancher, {Stephen T.}",
year = "1992",
doi = "10.1001/archneur.1992.00530350037016",
language = "English (US)",
volume = "49",
pages = "1123--1130",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Effect of long-term therapy on the pharmacodynamics of levodopa

T2 - Relation to on-off phenomenon

AU - Nutt, John

AU - Woodward, William

AU - Carter, Julie

AU - Gancher, Stephen T.

PY - 1992

Y1 - 1992

N2 - To determine how the response to levodopa is altered by long-term therapy, we examined the dose response to 2-hour infusions of levodopa in three groups of parkinsonian patients: those who were previously untreated, those who exhibited stable responses, and those who exhibited fluctuating responses to levodopa therapy, using tapping speed as an index of bradykinesia. The baseline tapping speed was greater in the patients with stable responses than in the untreated patients, probably representing a “long-duration response” to levodopa therapy. A “short-duration response”, indicated by an increase in tapping speed lasting hours, was observed in most patients in all groups. The onset of the short-duration effect was more rapid and the incremental increase in tapping speed was twice as large in the patients with fluctuating responses compared with the untreated patients and patients with stable responses. The duration of the short-duration effect was greatest in the untreated group but did not differ between the groups with stable and fluctuating responses. Dyskinesia was not observed in any of the de novo patients but was observed in three of 12 patients with stable responses and eight of nine patients with fluctuating responses to levodopa therapy. Dyskinesia appeared before or with the antiparkinsonian effects in patients with stable responses, giving no indication of a higher threshold for dyskinesia in these patients compared with those with fluctuating responses. The plasma half-life clearance, volume of distribution, and maximum plasma concentrations of levodopa did not differ among groups. We conclude that (1) part of what has been considered an extended short-duration response to levodopa therapy in patients with stable responses represents instead the long-duration response; (2) a short-duration response, albeit subtle, is present in most patients from the initiation of levodopa therapy; and (3) an increase in the magnitude of the short-duration response and the appearance of dyskinesia cause the fluctuations to become clinically important, whereas a shortening of the duration of the response is not critical.

AB - To determine how the response to levodopa is altered by long-term therapy, we examined the dose response to 2-hour infusions of levodopa in three groups of parkinsonian patients: those who were previously untreated, those who exhibited stable responses, and those who exhibited fluctuating responses to levodopa therapy, using tapping speed as an index of bradykinesia. The baseline tapping speed was greater in the patients with stable responses than in the untreated patients, probably representing a “long-duration response” to levodopa therapy. A “short-duration response”, indicated by an increase in tapping speed lasting hours, was observed in most patients in all groups. The onset of the short-duration effect was more rapid and the incremental increase in tapping speed was twice as large in the patients with fluctuating responses compared with the untreated patients and patients with stable responses. The duration of the short-duration effect was greatest in the untreated group but did not differ between the groups with stable and fluctuating responses. Dyskinesia was not observed in any of the de novo patients but was observed in three of 12 patients with stable responses and eight of nine patients with fluctuating responses to levodopa therapy. Dyskinesia appeared before or with the antiparkinsonian effects in patients with stable responses, giving no indication of a higher threshold for dyskinesia in these patients compared with those with fluctuating responses. The plasma half-life clearance, volume of distribution, and maximum plasma concentrations of levodopa did not differ among groups. We conclude that (1) part of what has been considered an extended short-duration response to levodopa therapy in patients with stable responses represents instead the long-duration response; (2) a short-duration response, albeit subtle, is present in most patients from the initiation of levodopa therapy; and (3) an increase in the magnitude of the short-duration response and the appearance of dyskinesia cause the fluctuations to become clinically important, whereas a shortening of the duration of the response is not critical.

UR - http://www.scopus.com/inward/record.url?scp=0026480977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026480977&partnerID=8YFLogxK

U2 - 10.1001/archneur.1992.00530350037016

DO - 10.1001/archneur.1992.00530350037016

M3 - Article

C2 - 1444877

AN - SCOPUS:0026480977

VL - 49

SP - 1123

EP - 1130

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 11

ER -